Robert Blum, Cytokinetics CEO
Cytokinetics gets an 'incremental' win for delayed heart drug
Cytokinetics’s aficamten is better than the standard of care in a heart muscle disease, the company said Tuesday. The development is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
